Press releases
2024
4 October, 2024
Change in the Board of Directors of Egetis Therapeutics
30 September, 2024
NOTICE OF EXTRAORDINARY GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)
30 September, 2024
Egetis Therapeutics has successfully carried out directed share issuances amounting to SEK 300 million
30 September, 2024
Egetis Therapeutics announces the intention to carry out directed share issuances of approximately SEK 300 million
19 September, 2024
Egetis submits a patent application to the United States Patent and Trademark Office for “Processes of Preparation” of tiratricol
28 August, 2024
New post-hoc analysis reports effects of tiratricol on patient-centered outcome measures in patients with MCT8 deficiency
22 August, 2024
Interim report Q2 2024
21 August, 2024
New data shows tiratricol (Emcitate®) treatment in patients with MCT8 deficiency is associated with survival benefits
19 June, 2024
Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency
3 May, 2024
Interim report Q1 2024
24 April, 2024
The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)
15 April, 2024
Egetis Therapeutics’ 2023 Annual Report published
22 February, 2024
Year-End report January-December 2023
2023
19 December, 2023
Egetis highlights recent major milestones, status of ReTRIACt trial and gives a corporate update at Investor Day in Stockholm today
14 December, 2023
Egetis’ Investor Day on December 19: Agenda and Registration Details
13 December, 2023
Egetis provides update on disease awareness and the Expanded Access Program for tiratricol (Emcitate) in the USA
1 December, 2023
Save the Date: Egetis to host Investor Day on December 19, 2023